114 related articles for article (PubMed ID: 3100013)
1. Short-term chemotherapy of poor-prognosis metastatic breast cancer with three non-cross resistant chemotherapy regimens. A Southwest Oncology Group Study.
Ahmann FR; Pugh R
Cancer; 1987 Jan; 59(2):239-44. PubMed ID: 3100013
[TBL] [Abstract][Full Text] [Related]
2. Adriamycin, vinblastine and mitomycin C as second-line chemotherapy in advanced breast cancer.
Sulkes A; Gez E; Pfeffer MR; Catane R; Isacson R; Biran S
Cancer Chemother Pharmacol; 1986; 18(2):162-7. PubMed ID: 3791561
[TBL] [Abstract][Full Text] [Related]
3. Doxorubicin, mitolactol (dibromodulcitol), and mitomycin C treatment for patients with metastatic breast cancer previously treated with cyclophosphamide, methotrexate, 5-FU, vincristine, and prednisone (CMFVP).
DiStefano A; Yap HY; Blumenschein GR
Cancer Treat Rep; 1981; 65(1-2):33-8. PubMed ID: 7013977
[TBL] [Abstract][Full Text] [Related]
4. Mitomycin C in metastatic breast cancer resistant to hormone therapy and conventional chemotherapy.
De Lena M; Jirillo A; Brambilla C; Villa S
Tumori; 1980 Aug; 66(4):481-87. PubMed ID: 7414712
[TBL] [Abstract][Full Text] [Related]
5. First, second and third line chemotherapy programs in metastatic breast carcinoma.
Rizel S; Sulkes A; Gez E; Brufman G; Biran S
Isr J Med Sci; 1981; 17(9-10):946-53. PubMed ID: 6171542
[TBL] [Abstract][Full Text] [Related]
6. Combination chemotherapy of advanced breast cancer. Comparison of dibromodulcitol, doxorubicin, vincristine, and fluoxymesterone to thiotepa, doxorubicin, vinblastine, and fluoxymesterone: an Eastern Cooperative Oncology Group Study.
Skeel RT; Andersen JW; Tormey DC; Benson AB; Asbury RF; Falkson G
Cancer; 1989 Oct; 64(7):1393-9. PubMed ID: 2505919
[TBL] [Abstract][Full Text] [Related]
7. A randomized study of intensive versus moderate chemotherapy programs in metastatic breast cancer.
Rosner D; Nemoto T; Lane WW
Cancer; 1987 Mar; 59(5):874-83. PubMed ID: 3815266
[TBL] [Abstract][Full Text] [Related]
8. Mitoxantrone, cyclophosphamide, and 5-fluorouracil in the treatment of hormonally unresponsive metastatic breast cancer.
Holmes FA; Yap HY; Esparza L; Buzdar AU; Hortobagyi GN; Blumenschein GR
Semin Oncol; 1984 Sep; 11(3 Suppl 1):28-31. PubMed ID: 6385262
[TBL] [Abstract][Full Text] [Related]
9. Mitomycin, doxorubicin, and vinblastine as second-line chemotherapy in patients with advanced breast cancer.
Borovik R; Epelbaum R; Cohen Y; Robinson E
Cancer Treat Rep; 1986 Apr; 70(4):517-8. PubMed ID: 3698045
[TBL] [Abstract][Full Text] [Related]
10. A new six-drug antiblastic regimen (R 14) at low doses (micropolychemotherapy) compared to CMF in the treatment of metastatic breast cancer: phase III study.
Pannuti F; Iafelice G; Martoni A; Fruet F; Angelelli B; Casadei M
Chemioterapia; 1984 Aug; 3(4):216-9. PubMed ID: 6398121
[TBL] [Abstract][Full Text] [Related]
11. Mitomycin C and vinblastine chemotherapy for advanced breast cancer.
Konits PH; Aisner J; van Echo DA; Lichtenfeld K; Wiernik PH
Cancer; 1981 Sep; 48(6):1295-8. PubMed ID: 6791808
[TBL] [Abstract][Full Text] [Related]
12. Vincristine, adriamycin, and mitomycin (VAM) therapy for previously treated breast cancer. A preliminary report.
Oster MW; Park Y
Cancer; 1983 Jan; 51(2):203-5. PubMed ID: 6821812
[TBL] [Abstract][Full Text] [Related]
13. Combination chemotherapy and high-dose cyclophosphamide intensification for poor prognosis breast cancer. A Southwest Oncology Group Study.
Ellis GK; Green S; Schulman S; Tranum BL; Goldberg RS; Livingston RB
Cancer; 1989 Dec; 64(12):2409-15. PubMed ID: 2684382
[TBL] [Abstract][Full Text] [Related]
14. Combination chemotherapy for advanced breast cancer: two regimens containing adriamycin.
Kennealey GT; Boston B; Mitchell MS; Knobf MK; Bobrow SN; Pezzimenti JF; Lawrence R; Bertino JR
Cancer; 1978 Jul; 42(1):27-33. PubMed ID: 667798
[TBL] [Abstract][Full Text] [Related]
15. Response and survival in advanced breast cancer after two non-cross-resistant combinations.
Brambilla C; De Lena M; Rossi A; Valagussa P; Bonadonna G
Br Med J; 1976 Apr; 1(6013):801-4. PubMed ID: 1260337
[TBL] [Abstract][Full Text] [Related]
16. Combination chemotherapy and adriamycin in patients with advanced breast cancer. A Southwest Oncology Group study.
Hoogstraten B; George SL; Samal B; Rivkin SE; Costanzi JJ; Bonnet JD; Thigpen T; Braine H
Cancer; 1976 Jul; 38(1):13-20. PubMed ID: 947510
[TBL] [Abstract][Full Text] [Related]
17. Adriamycin plus vincristine compared to and combined with cyclophosphamide, methotrexate, and 5-fluorouracil for advanced breast cancer.
De Lena M; Brambilla C; Morabito A; Bonadonna G
Cancer; 1975 Apr; 35(4):1108-15. PubMed ID: 1116104
[TBL] [Abstract][Full Text] [Related]
18. Adriamycin in combination for the treatment of breast cancer: a Southwest Oncology Group study.
Tranum B; Hoogstraten B; Kennedy A; Vaughn CB; Samal B; Thigpen T; Rivkin S; Smith F; Palmer RL; Costanzi J; Tucker WG; Wilson H; Maloney TR
Cancer; 1978 Jun; 41(6):2078-83. PubMed ID: 657081
[TBL] [Abstract][Full Text] [Related]
19. Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer.
Keller AM; Mennel RG; Georgoulias VA; Nabholtz JM; Erazo A; Lluch A; Vogel CL; Kaufmann M; von Minckwitz G; Henderson IC; Mellars L; Alland L; Tendler C
J Clin Oncol; 2004 Oct; 22(19):3893-901. PubMed ID: 15459210
[TBL] [Abstract][Full Text] [Related]
20. Low dose chemotherapy of metastatic breast cancer with cyclophosphamide, adriamycin, methotrexate, 5-fluorouracil (CAMF) versus sequential cyclophosphamide, methotrexate, 5-fluorouracil (CMF) and adriamycin.
Creech RH; Catalano RB; Harris DT; Engstrom PF; Grotzinger PJ
Cancer; 1979 Jan; 43(1):51-9. PubMed ID: 367574
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
